Mark Douglas Smith Sells 1,157 Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Mark Douglas Smith sold 1,157 shares of the stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $230.55, for a total transaction of $266,746.35. Following the completion of the sale, the director owned 9,680 shares of the company’s stock, valued at approximately $2,231,724. This trade represents a 10.68% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jazz Pharmaceuticals Stock Performance

Shares of Jazz Pharmaceuticals stock traded up $0.05 during mid-day trading on Wednesday, hitting $226.93. 679,885 shares of the stock were exchanged, compared to its average volume of 985,955. Jazz Pharmaceuticals PLC has a 12 month low of $105.00 and a 12 month high of $243.32. The company has a 50-day simple moving average of $219.28 and a 200 day simple moving average of $189.60. The company has a market capitalization of $14.26 billion, a P/E ratio of -11,340.83, a P/E/G ratio of 0.20 and a beta of 0.32. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.85 and a current ratio of 2.04.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 EPS for the quarter. The company had revenue of $1.07 billion during the quarter. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%. Sell-side analysts anticipate that Jazz Pharmaceuticals PLC will post 22.09 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on JAZZ shares. Robert W. Baird set a $252.00 price target on Jazz Pharmaceuticals in a research note on Wednesday, May 6th. Weiss Ratings downgraded Jazz Pharmaceuticals from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday. Leerink Partners upped their price target on Jazz Pharmaceuticals from $215.00 to $225.00 and gave the company an “outperform” rating in a research report on Wednesday, April 22nd. Barclays increased their price target on shares of Jazz Pharmaceuticals from $234.00 to $253.00 and gave the stock an “overweight” rating in a report on Wednesday, May 27th. Finally, Piper Sandler upped their target price on shares of Jazz Pharmaceuticals from $232.00 to $301.00 and gave the stock an “overweight” rating in a report on Friday, May 22nd. Sixteen investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $246.06.

Institutional Trading of Jazz Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the business. Royal Bank of Canada increased its position in shares of Jazz Pharmaceuticals by 96.5% in the first quarter. Royal Bank of Canada now owns 67,614 shares of the specialty pharmaceutical company’s stock worth $8,394,000 after purchasing an additional 33,210 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in Jazz Pharmaceuticals by 147.7% during the first quarter. Goldman Sachs Group Inc. now owns 351,609 shares of the specialty pharmaceutical company’s stock valued at $43,652,000 after purchasing an additional 209,667 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Jazz Pharmaceuticals by 4.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 197,174 shares of the specialty pharmaceutical company’s stock worth $24,479,000 after buying an additional 7,954 shares in the last quarter. Focus Partners Wealth increased its holdings in shares of Jazz Pharmaceuticals by 3.4% in the 1st quarter. Focus Partners Wealth now owns 4,623 shares of the specialty pharmaceutical company’s stock worth $574,000 after buying an additional 154 shares during the last quarter. Finally, Geneos Wealth Management Inc. increased its holdings in shares of Jazz Pharmaceuticals by 57.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock worth $47,000 after buying an additional 137 shares during the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.